| Document |
Document Title |
|
JP4847320B2 |
A method of evaluating memory/ learning functions with the use of a model with glutamic acid N-methyl-D-aspartate (NMDA) type receptor hypofunction as an animal model for schizophrenia and with the use of reference memory task, wherein t...
|
|
JP2011529053A |
Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a comb...
|
|
JP2011190238A |
To provide a novel cyclic squaric acid amide derivative or a salt thereof, and a prophylactic and/or therapeutic agent comprising at least one thereof as an active ingredient, which is particularly used for diseases against which a calci...
|
|
JP4716980B2 |
Compounds of formula: (1) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia are described. Processes...
|
|
JP2011126887A |
To provide a new method for producing a dibenzothiazepine derivative useful as a starting material for producing 11-[4-(2-(2-hydroxyethoxy)ethyl)]-1-piperazinylbenzothiazepi
ne derivative useful as an antipsychotic agent.This compound ex...
|
|
JP4711953B2 |
A pharmaceutical useful as a therapeutic agent and a preventive agent for hyperlipemia, and a pharmaceutical useful as a therapeutic agent and a preventive agent for hepatic disorders associated with cholestasis, particularly, primary bi...
|
|
JP4688383B2 |
Preparation of dibenzothiazepine derivatives of formula (5) comprises reaction of 1-(X)-2-(R4)-3-(R3)-4-(R2)-5-(R5)-nitrobenzene derivatives (1) with thiosalicylic acid derivatives of formula (2), reduction of the resultant 2-nitro-2'-ca...
|
|
JP2011510960A |
The invention relates to a method for the preparation of 11-(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo [b,f]-1,4-thiazepine and pharmaceutically acceptable salts thereof comprising the reaction of 1-[2-(hydroxyethoxy)-ethyl]pipe...
|
|
JP2011046671A |
To provide a production method in which foaming is controlled, and which can improve the volume efficiency in an industrial scale in the production of 2-(2-[4-(dibenzo[b,f][1,4]thiazepin-11-yl)-1-piperazinyl]eth
oxy)ethanol.A mixture con...
|
|
JP4637584B2 |
Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid ² protein production and neurological disorders such as Alzheimer's dis...
|
|
JP4628366B2 |
The present invention relates to novel macrocyclic compounds of the formula wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17,...
|
|
JP4603534B2 |
The present invention provides a drug serving as a muscular relaxation accelerating agent, a therapeutic agent for left ventricular diastolic dysfunction, a therapeutic agent for angina pectoris, a therapeutic agent for acute pulmonary e...
|
|
JP4590981B2 |
|
|
JP2010248215A |
To provide a therapeutic and prophylactic agent for cardiac failure caused by myocardial diastolic dysfunction or left ventricular diastolic dysfunction, angina pectoris caused by diastolic coronary circulation dysfunction, and catechola...
|
|
JP2010248216A |
To provide a compound useful for treatment of neurological disorders relevant to formation of amyloid β protein and of neurological disorders such as Alzheimer's disease.There is disclosed the compound having a structure expressed by fo...
|
|
JP2010531292A |
Formula (I) below: and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least one symptom or condition associated with schizophr...
|
|
JP4529030B2 |
A kit used to screen agents for antiprion activity comprising a yeast (A) having the (PSI+) phenotype and an antibiogram, is new. Independent claims are also included for: (1) method of screening compounds for antiprion activity comprisi...
|
|
JP4497472B2 |
Drugs useful for the treatment and prevention of hyperlipidemia, moreover drugs useful for the treatment and prevention of cholestasis-caused hepatopathy, particularly primary biliary cirrhosis and primary sclerosing cholangitis, and dru...
|
|
JP4494780B2 |
The present invention relates to compounds of formula (I): wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport...
|
|
JP4491131B2 |
Disclosed are thiazolobenzoheterocycles of the general formulaIncluding their isomers, racemates, enantioners and salts thereof, as well as processes for preparing these compounds and medicaments containing them. Also disclosed are novel...
|
|
JP2010520237A |
The present invention is directed to substituted benzodiazepinones, benzoxazepinones and benzothiazepinones compounds that are sodium channel blockers useful for the treatment of chronic and neuropathic pain. The compounds of the present...
|
|
JP2010520298A |
Disclosed herein are novel polymorphs of 7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin
-11-yl)amino]heptanoic acid S,S-dioxide. Also described herein are novel pharmaceutical compositions comprising one or more 7-[(3-chlor...
|
|
JPWO2008102908A1 |
Providing new herbicides. General formula (1):[In the formula, Q is -N (R)5) SO2R6Represents R5And R6Represents an alkylene or the like that may be bonded to each other to form a ring. ] Is a haloalkyl sulfone anilide derivative or a sal...
|
|
JP2010514684A |
This invention relates to novel compounds having the structural Formula (I) below: and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxi...
|
|
JP2010514683A |
This invention relates to novel compounds having the structural Formula I below: and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis ...
|
|
JP2010514682A |
This invention relates to novel compounds having the structural Formula (I) below: and their pharmaceutically acceptable salts, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least...
|
|
JP4458514B2 |
A method for producing highly pure enamines, which comprises a step of reacting an aldehyde or ketone with an amine and a step of treating the resulting reaction mixture with an acidic aqueous solution at between 0 DEG C and 30 DEG C.
|
|
JP4441261B2 |
The present invention relates to compounds of formula (I), wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport...
|
|
JP2010053044A |
To provide a method for producing 11-chlorodibenzo[b,f][1,4]thiazepine, which can improve the quality, yield and liquid-separating property of the 11-chlorodibenzo[b,f][1,4]thiazepine and can improve the efficiency of workability in an i...
|
|
JP4414237B2 |
The present invention relates to methods for the preparation of crystalline quetiapine hemifumarate.
|
|
JP2010502680A |
The invention relates to novel heterocyclic compounds of the formula in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
|
|
JP4364944B2 |
The invention provides novel cryptophycin compounds which can be useful for disrupting the microtubulin system, as anti-neoplastic agents, and for the treatment of cancer. The invention further provides a formulation for administering th...
|
|
JP2009537615A |
The present invention relates to 2-alkoxy-3,4,5-trihydroxyalkylamide benzothiazepine compounds, to pharmaceutical compositions comprising such compounds, to methods of treatment comprising administering such compounds, to processes for t...
|
|
JP4331264B2 |
A novel calcium receptor active compound having the formula is provided: Ar1-ÄCR<1> R<2>ÜP-X-ÄCR<3>R<4>Üq-ÄCR<5>R<6>Ü-NR<7>-ÄCR<8>R<9>Ü-A
r2 wherein: Ar1 is selected from the group consisting of aryl, heteroaryl, bis(arylmethyl)a...
|
|
JP2009529518A |
The invention provides a new method for treating disorders associated with activation of the Notch signal transduction pathway comprising administering an effective amount of a compound of Formula (I), in free form or in a pharmaceutical...
|
|
JP2009529062A |
Provided is an improved synthesis of quetiapine and pharmaceutically acceptable salts.
|
|
JP2009527458A |
A dibenzothiazepine compound is suitably prepared by subjecting a 2-amino-2′-carboxy-diphenylsulfide compound to dehydration-condensation reaction in the presence of an acidic catalyst; the 2-amino-2′-carboxy-diphenylsulfide compound...
|
|
JP2009521513A |
The present invention relates generally to a method of treatment and in particular a method of treating a subject exhibiting symptoms of kidney failure or are at risk of developing same. Even more particularly, the present invention prov...
|
|
JP2009102345A |
To provide crystalline 11-(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl)-dibenzo[b, f][1, 4]thiazepine which can be used for the treatment of psychoses.The crystalline 11-(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl)-dibenzo[b, f][1, 4]thia...
|
|
JP2009516708A |
The present invention is directed to liquid formulations of the pharmaceutical compound 1 1-piperazin-1-yldibenzo[b,f][1,4]thiazepine as well as preparations, and pharmaceutical uses thereto.
|
|
JP2009516706A |
The present invention is directed to a crystalline form the pharmaceutical compound 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine as well as compositions, preparations, and pharmaceutical uses thereof.
|
|
JP2009516705A |
The present invention is directed to salts the pharmaceutical compound 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine as well as compositions, preparations, and pharmaceutical uses thereof.
|
|
JP2009513510A |
The present invention relates to macro-cyclic compounds of formula (I), wherein R1, is (C1-8)alkyl, (C1-4)alkoxy(C1-4)alkyl, hydroxy(C1-6)alkyl, (C1-4)alkylthio(C1-4)alkyl, (C1-6)alkenyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-4)alkyl, pi...
|
|
JP2009513498A |
This invention describes a process for the production of C1-C15-fragments of epothilones and derivatives thereof, in which a C1-C6-fragment is linked with a C7-C12-fragment to a C1-C12-fragment, and the latter then is reacted with a C13-...
|
|
JP4225694B2 |
A process for the preparation of I:in which R and R1 have the meanings reported in the description, that comprises the enzymatic kinetic resolution by transesterification with aminoalcohols of 3-phenylglycidates of formula I:is described.
|
|
JP4219166B2 |
The invention relates to novel benzazepines and related heterocyclic derivatives (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes f...
|
|
JP2009501178A |
The invention relates to the compound of the formula (A) and also to its physiologically acceptable salts. The compound is suitable as, for example, a hypolipidemic.
|
|
JP2008546712A |
The present invention discloses novel methods and compositions for viral inhibition, particularly inhibition of HCV and SARS. The invention also provides compositions including novel oxoazepanylacetamide derivatives useful for viral inhi...
|
|
JP2004516324A5 |
|
|
JP4181291B2 |
A compound comprising a substituent of the formula (II) is disclosed as an HIV protease inhibitor. Intermediates for making such compounds and processes for making such intermediates are also disclosed.
|
